Arvinas to Present at Stifel 2021 Virtual Healthcare Conference
November 10, 2021 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas to Participate in Upcoming Virtual Investor Conferences
September 01, 2021 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 05, 2021 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein Degrader ARV-471
July 22, 2021 07:00 ET
|
Arvinas Inc.
– Collaboration combines Arvinas’ investigational estrogen receptor-targeting breast cancer therapy with Pfizer’s deep experience in breast oncology therapeutics – – ARV-471 is currently in Phase 2...
Arvinas to Present at the 42nd Annual Goldman Sachs Global Healthcare Conference
June 03, 2021 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., June 03, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021
April 05, 2021 16:30 ET
|
Arvinas Inc.
NEW HAVEN, Conn., April 05, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...